RxSight, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 13, 2026, discloses significant executive leadership changes at RxSight, Inc. (RXST). The filing details the appointment of a new President and Chief Executive Officer (CEO) and the transition of the former CEO to a new role, alongside the adoption of a new equity incentive plan.
Key Financial Metrics and Compensation
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels. However, it discloses specific compensation figures related to the executive transition:
- New CEO (Aziz Mottiwala): Annual base salary of $750,000; target annual bonus up to 90% of base; 2026 prorated cash bonus of $337,500.
- New CEO Equity: Total grant value of $14,000,000, consisting of $2,000,000 in stock options and $12,000,000 in restricted stock units (RSUs).
- Former CEO (Ron Kurtz, M.D.): Retains annual base salary of $740,000 as Chief Medical Officer; eligible for annual bonus up to 100% of base.
- Former CEO Retention: Eligible for retention bonuses totaling $1,480,000 ($370,000 paid quarterly over two years) and a grant of 500,000 RSUs.
- Severance Provisions: Both executives have agreements providing for lump-sum payments (12-18 months of salary and bonus) and equity acceleration in the event of termination without cause or resignation for good reason, with enhanced terms upon a change in control.
Material Changes
The primary material change is the leadership succession plan effective July 20, 2026:
- Appointment: Aziz Mottiwala appointed as President and CEO, replacing Ron Kurtz, M.D.
- Role Transition: Dr. Kurtz transitions from CEO to Chief Medical Officer (CMO).
- Board Changes: Dr. Kurtz resigned from the Board of Directors; Mr. Mottiwala was appointed to fill the vacancy as a Class II director.
- Plan Adoption: The Board adopted the RxSight, Inc. 2026 Inducement Equity Incentive Plan, reserving 3,500,000 shares for new employee inducement grants without stockholder approval.
Outlook, Risks, and Contingencies
The filing indicates a strategic shift in commercial leadership, bringing in Mr. Mottiwala with extensive experience in pharmaceutical commercialization (Tarsus, Opiant, Avanir, Allergan). The company has structured significant financial contingencies to ensure leadership stability:
- Retention Risk Mitigation: Substantial retention bonuses and equity grants for Dr. Kurtz are designed to ensure a smooth transition to the CMO role.
- Change in Control: Both executives have "golden parachute" provisions that trigger full equity vesting and significant cash severance if the company is acquired and they are terminated or resign for good reason.
- Regulatory Compliance: The new equity plan was adopted under Nasdaq Listing Rule 5635(c)(4), requiring strict adherence to inducement standards.
Investor Verification Checklist
- Verify the exact grant date and share count for Mr. Mottiwala's $14 million equity package, as the grant date depends on the filing of Form S-8.
- Confirm the vesting schedule specifics for Dr. Kurtz's 500,000 RSUs and the timing of the first retention bonus payment (August 1, 2026).
- Review the full text of the "Mottiwala Employment Agreement" and "Kurtz Transition Agreement" when filed as exhibits to subsequent periodic reports for detailed termination definitions.
- Monitor the company's cash position to assess the impact of the immediate $337,500 bonus to Mr. Mottiwala and future retention payments to Dr. Kurtz.
- Check for any subsequent press releases or filings regarding the commercial strategy under the new CEO.